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Background: Hospital antimicrobial stewardship strategies, such as ‘Start Smart, Then Focus’ in the UK, balance
the need for prompt, effective antibiotic treatment with the need to limit antibiotic overuse using ‘review and
revise’. However, only a minority of review decisions are to stop antibiotics. Research suggests that this is due to
both behavioural and organizational factors.
Objectives: To develop and optimize the Antibiotic Review Kit (ARK) intervention. ARK is a complex digital, organ-
izational and behavioural intervention that supports implementation of ‘review and revise’ to help healthcare
professionals safely stop unnecessary antibiotics.
Methods: A theory-, evidence- and person-based approach was used to develop and optimize ARK and its
implementation. This was done through iterative stakeholder consultation and in-depth qualitative research
with doctors, nurses and pharmacists in UK hospitals. Barriers to and facilitators of the intervention and its imple-
mentation, and ways to address them, were identified and then used to inform the intervention’s development.
Results: A key barrier to stopping antibiotics was reportedly a lack of information about the original prescriber’s
rationale for and their degree of certainty about the need for antibiotics. An integral component of ARK was the
development and optimization of a Decision Aid and its implementation to increase transparency around initial
prescribing decisions.
Conclusions: The key output of this research is a digital and behavioural intervention targeting important
barriers to stopping antibiotics at review (see http://bsac-vle.com/ark-the-antibiotic-review-kit/ and http://anti
bioticreviewkit.org.uk/). ARK will be evaluated in a feasibility study and, if successful, a stepped-wedge cluster-
randomized controlled trial at acute hospitals across the NHS.
Introduction
Antimicrobial resistance is an important public health risk, resulting
in increased healthcare costs, treatment failure and mortality.1
Antibiotic exposure increases the risk of antibiotic resistance,2,3 so
it is vital to reduce antibiotic over-use.4 Two successful strategies in
primary care are avoiding and delaying prescribing antibiotics.5–8
However, these approaches are not appropriate in hospitals, as
patients may have a life-threatening bacterial infection for which
delaying antibiotics increases mortality. Hospitals therefore need
to balance early and effective antibiotic treatment with reducing
unnecessary antibiotic use.
‘Start Smart, Then Focus’ is an antimicrobial stewardship initia-
tive developed by the UK Department of Health.9 It promotes early
initiation of antibiotics followed by active review and revision of
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antibiotic prescriptions within 48–72 h, with five actions: stop, con-
tinue, change (narrow/broaden), move from intravenous to oral
formulations, or move to outpatient parenteral antimicrobial
therapy (OPAT). Although often started appropriately, in practice
few antibiotic prescriptions get modified following initial prescrip-
tion.10 There is currently a lack of evidence regarding how best to
implement ‘review and revise’ in clinical practice.11 Several
behavioural and organizational factors can impede ‘review and re-
vise’, including a reluctance on the part of healthcare professionals
(HCPs) to revise antibiotic prescriptions made by others, even when
a patients’ clinical status has evolved.12
The aim of the current research was to develop the Antibiotic
Review Kit (ARK) intervention. ARK aims to safely reduce antibiotic
use through increasing effective implementation of ‘review and
revise’, focusing on facilitating stopping antibiotics when they are
no longer needed. The target population is HCPs involved in admin-
istering or prescribing antibiotics in acute and general medicine,
and associated medical specialities. This paper comprehensively
describes the planning, development and optimization of ARK.
Methods and results
ARK is a complex digital, behavioural and organizational
intervention that was developed using an integrated approach to
intervention development, combining theory-, evidence- and
person-based approaches.13–15 This approach has been used
successfully to develop digital and behavioural interventions in a
variety of contexts, including reducing antibiotic usage in primary
care.16,17 ARK was developed and optimized using a novel applica-
tion of the person-based approach that used iterative stakeholder
consultation with HCPs. Stakeholder consultation has long been
advocated as a method for maximizing the acceptability and feasi-
bility of interventions and their implementation.18 However, it has
been little used in this field,19 and there are few explicit descrip-
tions of how it can be used in practice.20 The intervention was
developed in three iterative stages: (1) initial intervention planning
and development; (2) optimization of the digital intervention (an
online educational, motivational and decision support tool); and
(3) optimization of the implementation. Evidence of potential bar-
riers and facilitators to stopping antibiotics at ‘review and revise’
and effective implementation was collated at each stage using
stakeholder consultation (Table 1). All workshops was recorded
and detailed notes were taken by at least two minute-takers at
each workshop, with audio recordings used as a cross-reference.
Where appropriate, additional qualitative research was used
to gain a more in-depth understanding of the intervention’s
target users’ needs, issues, context and challenges. This
evidence informed the planning, development and optimization
of the intervention and its implementation at each stage of
development.
The methods and key results for each stage are presented
below.
Table 1. Summary of aims and outcomes of the stakeholder workshops
Stakeholder
workshop Aims Participants Feedback from workshop Outcomes of workshop
Workshop 1, March
2016 (Stage 1)
To explore views on the
initial proposed design
and elements of the
intervention and identify
key acceptability and
feasibility issues.
18 healthcare professionals
working in infectious disease,
microbiology, paediatrics,
geriatrics, public health, general
medicine and/or acute medicine.
Information about the
context of ‘review and
revise’ and stopping
antibiotics in hospitals,
key clinical issues, and
experiences of existing
antimicrobial steward-
ship initiatives.
Identification of barriers and
facilitators to stopping
antibiotics at ‘review
and revise’ to inform
intervention planning.
This included 8 consultant-grade
doctors, 8 training-grade doctors,
a pharmacist and a nurse.
Development of initial
intervention components
and materials.
Workshop 2,
December 2016
(Stage 3)
To elicit feedback on the
proposed implementa-
tion plan and documents
(implementation phases,
audit and feedback,
checklist and audit tool).
12 healthcare professionals
working in infectious diseases,
microbiology, general medicine
and/or acute medicine.
This included 9 consultant-grade
doctors, 1 training-grade doctor
and 2 pharmacists.
Feedback on the main tasks
and timeline of the im-
plementation phases.
Feedback on the initial plan
for the audit tool.
Refinement of the number and
content of the
implementation phases.
Development and refinement
of the implementation
documents.
Workshop 3,
February 2017
(Stage 3)
To elicit views on the com-
plete ARK intervention
from teams who were
planning to implement
it shortly.
21 healthcare professionals
working in infectious disease,
microbiology, general medicine
and/or acute medicine from 4
hospitals who were candidates
for taking part in the feasibility
and pilot studies.
Feedback on how teams
could implement the
Decision Aid categories
and audit tool in their
hospital.
Refinement of the implemen-
tation phases and
documents.
Refinement of the digital
materials.
Clarifications about the
required steps of the
implementation phases.This included 12 consultant-grade
doctors, 4 training-grade doctors
and 5 pharmacists.
Each workshop lasted around 3 h.
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Stage 1: initial intervention planning and development
Stage 1 involved the initial planning and development of the inter-
vention. This process was informed predominantly by the results
of Stakeholder Workshop 1 (Table 1), which provided the basis for
two key outputs: (i) ‘guiding principles’ to orientate the interven-
tion’s design by specifying intervention design objectives and
features for increasing engagement with the intervention;13–15
and (ii) a behavioural analysis to identify barriers to and facilitators
of stopping antibiotics at ‘review and revise’ (see Supplementary
data at JACOnline).
Through a series of co-design meetings, the co-authors of this
paper then identified suitable techniques to address the barriers to
stopping antibiotics identified by stakeholders and developed
prototype intervention materials. These were then refined using it-
erative online feedback from six stakeholders from the workshop.
Once intervention planning and development was complete, a
process-orientated logic model of the intervention was created to
describe the hypothesized causal relations between the interven-
tion’s key components/techniques and outcomes (Figure 1).21
A description of the intervention following TIDieR guidance was
also completed,22 and the elements of the intervention were
mapped onto a generic theoretical framework and taxonomy
(Supplementary data).23,24
Stakeholder Workshop 1
The first stakeholder workshop presented the aims of ARK and po-
tential intervention components (Table 1). Previous research into
methods to reduce antibiotic usage in hospitals was limited, and
therefore the initial plan was informed by previous interventions
targeting antibiotic reduction in primary care.7,17 Six intervention
components were initially proposed:
• A 30 min personalized digital education module for self-
completion.
• The introduction of antibiotic prescribing ‘moments’ (initial pre-
scription, ‘review and revise’), analogous to WHO hand-hygiene
‘moments’.25
• A standardized ‘review and revise’ pro forma and algorithm for
describing clinical presentation and deciding what diagnostic
tests would be needed to inform and optimize ‘review and
revise’ decisions.
• Regular antibiotic stewardship ward rounds and/or regular
ward pharmacist review.
• Regular 45–60 min peer-led seminars for discussing experien-
ces of ‘review and revise’.
• A patient leaflet.
Participants were asked for their feedback on the proposed
intervention components, their ideas and experiences, and exam-
ples of ‘review and revise’ in their hospitals.
Stakeholder feedback
Participants were sceptical about the acceptability of the digital
education module due to high workload and the large amount of
existing e-learning modules, which many found boring and point-
less. Although discussions about ‘review and revise’ were seen as
helpful, participants stated that it can be difficult to get people to
attend seminars. Alternative suggestions were to link in with ward
‘huddles’ and handover meetings.
THE
PROBLEM
‘Review and
revise’ and
stopping of
antibiotics is
suboptimal
(even when
review is
done,
antibiotics are
not stopped
even when
safe and
appropriate to
do so)
Effective
implementation
of ‘review and
revise’
procedures to
facilitate
stopping
unnecessary
antibiotics
promptly
For all staff • Provide Decision Aid to support decision making around
  antibiotic prescriptions
• Provide examples/instructions of how to use Decision Aid
• Provide tailored advice and encouragement based on
  monitoring (e.g. through discussion meetings based on data
  collection)
• Provide empowerment user stories/quotes about how easy
  HCPs found it to implement ARK processes*
• Provide information about ‘review and revise’ guidelines
  and how they fit with other relevant guidelines
• Provide information about shorter versus longer course
  antibiotic durations
• Provide information about health consequences of antibiotics
• Provide evidence for effectiveness of shorter versus longer
  antibiotic durations
• Provide positive user stories/quotes about the outcomes of
  ARK*
• Provide objects to support 'review and revise' (e.g. patient
  leaflet, prompts to use Decision Aid categories in practice)
• Provide example materials that the implementation
  team can use to prompt clinical team (e.g. posters)*
• Run kick-off meetings to introduce ARK to clinical teams
• Facilitate regular supportive discussion with clinical team
• Provide network for the implementation team
• Set targets for ‘review and revise’ and using ARK Decision
  Aid
• Support action planning for implementation*
↑ Skills
↑ Use of the
ARK Decision
Aid categories
Primary
outcome
↓ Antibiotic
exposure
(with non-
inferiority in
clinical
outcomes)
↑ Stopping
of antibiotic
prescriptions
within 72
hours
↑ Reviewing
and revising
antibiotics
(including
taking the
decision to
stop)
↑ Beliefs about
capabilities
↑ Intentions
↑ Social
influences
(social support)
↑ Environmental
resources
↑ Positive beliefs
about
consequences of
‘review and revise’
↑ Knowledge
ARK online tool
ARK Decision
Aid
ARK patient
leaflet
Data collection
and regular,
supportive
discussion with
clinical teams
For
implementation
team
ARK Resources
website
ARK Data
collection tool
Implementation
guidance
ARK Champion
network
Timely ‘review
and revise’
(within 48-72 h)
Documentation of
diagnostic
uncertainty
Clear
communication
between health
care professionals,
and with patients
INTERVENTION
TARGET
INTERVENTION
COMPONENT(S)
OUTCOMESPURPORTED
MEDIATORS
INTERVENTION
PROCESSES
INTERVENTION TECHNIQUES
*Techniques applicable to implementation team only
(ARK Champion and implementation team only)
Figure 1. ARK logic model summarizing key intervention components, techniques, processes, target behaviours and outcome (final model).
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One of the biggest problems stakeholders reported was that
initial prescription and ‘review and revise’ were undertaken by
different HCPs. The reason for initial prescription and degree of
certainty regarding the initial need for antibiotics was often un-
clear, meaning that the reviewer was reluctant to revise the initial
prescription in case they had missed something important about
the initial presentation. In the absence of accurate information
about the status of the patient at the initial prescription, stopping
was seen as riskier than continuing antibiotics. It was suggested
that acknowledging the degree of uncertainty in initial prescrip-
tions would be helpful. Participants felt that senior staff needed to
input into ‘review and revise’ decisions but had limited time. Whilst
junior doctors, pharmacists and nurses might have important roles
in supporting ‘review and revise’, they might lack confidence in
doing so. It was felt that HCPs would benefit from understanding
the consequences of stopping antibiotics, why it was safe, and
how restarting antibiotics (if needed) was acceptable. Analogies
were made to discharging patients, accepting that while a small
minority might need to be re-admitted, most did well.
Overall, participants disliked the idea of having a standardized
pro forma and algorithm, partly because of substantial challenges
in introducing it into diverse hospital contexts, with different,
competing policies and practices. Some hospitals had paper-based
prescribing, others e-prescribing. It was suggested that ARK would
need to integrate into existing routines and practices, and should
provide a selection of tools to facilitate implementation, such as a
system for flagging up prescriptions needing review, e.g. by using
pop-ups, stickers or highlighters on the drug chart.
Consultation outcomes
Stakeholder Workshop 1 highlighted a few key issues regarding
the intervention’s design and adjustments that needed to be
made to the initial plan and its components. Key guiding principles
for the intervention’s design are shown in Table 2.
Several changes were made to the intervention plan. Firstly, the
standardized pro forma and algorithm was replaced with a flexible
Decision Aid for communicating the degree of certainty surround-
ing the initial decision to prescribe antibiotics (Figure 2). Initial anti-
biotic prescriptions are categorized as either ‘possible’ risk of
infection (infection is less likely but antibiotics are being prescribed
as a precaution) or ‘probable’ risk of infection (infection is likely but
more information is required before finalizing the diagnosis/treat-
ment). At review, prescriptions are either stopped (no evidence of a
continued need for antibiotics) or finalized (decision made about
final agent, route and duration).
Secondly, the 30 min personalized digital education module
was changed to a brief online tool (7–10 min) to take into account
the demands on HCPs’ time and negative perceptions regarding
Table 2. The guiding principles for the development of the ARK intervention
Intervention design objectives Key features
To increase HCPs’ (a) motivation and
(b) confidence to stop antibiotics
• (a) Provide scientific evidence and case studies to convince HCPs that:
 Stopping antibiotics is safe.
 Continuing antibiotics puts patients at increased risk from antibiotic resistance.
• (b) Provide tools to support the ‘review and revise’ process and stopping antibiotics, including:
 The Decision Aid categories as a solution to the problem of not understanding how the original
prescriber viewed the patient’s presenting condition.
 The patient leaflet to support communicating ‘review and revise’ and the risks of antibiotics to
patients and to provide safety-netting advice.
To provide easily accessible tools that
are suitable for a range of staff groups
and grades (prescribers and
non-prescribers)
• Make tools easily accessible as web-based and phone app.
• Make the online tool very short, simple and engaging, suitable for busy doctors, pharmacists and
nurses.
To empower and support acceptable
and feasible implementation of
effective ‘review and revise’ across
a range of hospital contexts
• Offer a variety of implementation resources that can be adapted to a variety of clinical contexts.
• Promote the HCPs’ ownership of the implementation, giving them the opportunity to work out how
the resources could best be implemented within their context.
HCPs, healthcare professionals.
Patient with
uncertain diagnosis
Probable
diagnosis of infection
Final
antibiotic prescription
Possible
risk from infection
Stopped
antibiotic prescription
Standard patient monitoring as required
to check if antibiotics need to be stopped/restarted
Figure 2. ARK Decision Aid categories flow chart.
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length of other e-learning modules. Thirdly, peer-led seminars
were replaced with brief, regular, supportive discussions
embedded within routine clinical team meetings. Finally, it was
decided that the implementation team, including an ARK
Champion (site lead) and a small number of other HCPs represent-
ing key disciplines and staff grades, needed a selection of resour-
ces and guidance to help them implement ARK flexibly depending
on local needs. The development and optimization of these resour-
ces is discussed more fully below in the section describing Stage 3.
The final intervention logic model is shown in Figure 1 and a
complete description of the intervention can be found in the
Supplementary data.
Stage 2: optimization of the digital intervention
Ethics
Ethical approval for the qualitative research was obtained from the
London–Westminster Research Ethics Committee (REC: 16/LO/
0789). All participants provided written informed consent.
Design and procedure
In Stage 2, the key HCP intervention materials (online tool and
Decision Aid) were optimized through in-depth qualitative research
using think-aloud interviews with a broader range of HCPs who
were involved with antibiotic prescribing. The development and
optimization of the patient leaflet will be reported separately
(F. Mowbray, K. Sivyer, M. Santillo, N. Jones, T. E. A. Peto, A. S.
Walker, M. J. Llewelyn, L. Yardley, unpublished data).
Participants were recruited through the stakeholder network,
with stakeholders approaching colleagues at different hospitals to
ask them to promote the study to their colleagues. Interested indi-
viduals then directly contacted the research team to arrange an
interview. Face-to-face think-aloud interviews were carried out
with 20 HCPs (6 consultant-grade doctors, 6 training-grade doc-
tors, 6 pharmacists, 2 nurses) from six hospitals to elicit detailed
feedback on the online tool. Participants were asked to read each
page of the website (or the mobile-friendly version) and say aloud
what they were thinking while reading the pages. Interviews
lasted 40–60 min and were recorded and fully transcribed. Data
collection was an iterative process, with initial interviews leading
to modifications, followed by further interviews to assess these
modifications. Interview feedback and resulting modifications to
the online tool can be found below.
Feedback was collated into a table of positive and negative
comments for each page of the online tool (totalling 70 pages).26
Potential changes identified from these comments were discussed
with the core research team throughout intervention development
in order to agree modifications to the online tool.
Interview feedback
The think-aloud interviews elicited mainly positive views of the
online tool, but crucially identified that some clinicians were un-
convinced by earlier versions that antibiotics could be stopped
safely. Participants wanted more information about the evidence
regarding the risks and benefits of shorter versus longer courses
of antibiotics. They also suggested providing information about
current guidelines for antibiotic durations in different countries and
guidelines relating to ‘surviving sepsis’, as they considered these
important to informing ‘review and revise’. They requested more
explanation of the intervention and how the Decision Aid could
help to safely reduce antibiotic prescribing.
Intervention outcomes
The content of the online tool was refined. More information was
added about different clinical guidelines and the evidence for
shorter versus longer courses of antibiotics. A page was added to
clarify the roles of non-prescribers in supporting ‘review and revise’
to make the intervention more inclusive. The roles of senior mem-
bers of staff and specialists were made more explicit. Additional in-
formation was provided about how the Decision Aid would help to
safely reduce antibiotics. The Decision Aid categories were rede-
fined to make them easier to understand for different professional
groups and to make them more clinically accurate.
Stage 3: optimization of the implementation
Stage 3 developed and optimized the implementation guidance
and resources. These materials were informed by previous re-
search supporting the positive effects of audit and feedback on
antibiotic prescribing,27 and research that used the Theoretical
Domains Framework Implementation (TDFI) approach,28 to pro-
vide guidance and tools to support team-based implementation.
Refinements were informed by Stakeholder Workshops 2 and 3
(Table 1).
Stakeholder Workshop 2
This workshop presented an overview of the initial implementation
guidance and resources to participants from Workshop 1 (Table 1).
The following resources were presented:
• Phases of implementation and implementation checklist.
• Kick-off meeting slides for introducing ARK to clinical teams.
• Data collection tool.
Participants were asked to give feedback on the phases of im-
plementation and other resources, and to identify potential bar-
riers to implementation.
Stakeholder Workshop 3
This workshop presented the revised implementation guidance
and resources, including a spreadsheet version of the data collec-
tion tool that was aligned with the Commissioning for Quality and
Innovation (CQUIN) in place at the time.29 This workshop included
HCPs from hospitals that were candidates for the feasibility and
pilot studies, and therefore had a specific interest in understanding
how to implement ARK in their hospitals.
Stakeholder feedback
Participants in Stakeholder Workshop 2 expressed concerns about
how the implementation team would be trained and updated
about new developments in the long term. They also reported con-
cerns about incorporating the Decision Aid categories into practice,
including how long it would take to change the drug chart and
how to do so in e-prescribing systems. They suggested that it
Santillo et al.
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might be difficult communicating with different clinical teams
about ARK and that there might be poor completion of the
online tool before kick-off. Participants were unsure how data
collection would work, although it was felt it would be important
to show local rates for ‘review and revise’ and stopping
antibiotics.
Similar issues arose in Stakeholder Workshop 3. Participants
responded positively to the kick-off slides and rationale for ARK,
particularly the ‘Elevator pitch’, which provided a quick but direct
summary of the rationale for ARK. However, participants were still
unsure how best to implement the Decision Aid categories in prac-
tice, and wanted further clarification on how best to do data collec-
tion. Whilst the new data collection tool was seen as useful, it was
suggested that it needed simplifying. Participants also requested
that it provide other useful data (e.g. information about decisions
taken at review). Participants reported concerns around how
to facilitate understanding of the Decision Aid categories and
suggested that it would be helpful to have clinical scenarios in
the online tool to practise applying the Decision Aid categories.
Participants were also concerned about the potential impact of
staff turnover.
Intervention outcomes
The phases of implementation were adjusted to introduce piloting
the Decision Aid categories and the data collection tool to ensure
that hospitals had tested and were familiar with these processes
before implementing them. A new phase was added, which
focused on publicizing ARK to the clinical teams and encouraging
completion of the online tool to increase its uptake (Figure 3).
Several new resources were created. A spreadsheet data
collection tool was developed following Workshop 2 in response to
concerns about data collection, and refined following feedback at
Stakeholder Workshop 3 (e.g. simplifying the layout, clarifying
definitions and instructions, providing additional graphs). To sup-
port ongoing training and facilitate sharing resources between
hospitals, an ARK Network was developed for the implementation
team (e-mail list and teleconferences). The online resources were
also extended so that example materials from different hospitals
could be uploaded.
Finally, a short quiz was added to the online tool for participants
to practise and get feedback on applying the Decision Aid catego-
ries to clinical examples. The ‘Elevator pitch’ was also added to the
online tool to enhance the persuasiveness of the message about
the rationale for ARK.
The final phases of implementation and full behavioural ana-
lysis can be found in the Supplementary data.
Discussion
This paper describes the development of the ARK intervention,
which aims to safely reduce antibiotic use in hospitals through
stopping unnecessary antibiotics at ‘review and revise’.
Intervention development used a novel adaptation of the ‘person-
based approach’ to intervention development,13–15 which used
stakeholder consultation with HCPs involved in antibiotic prescrib-
ing to explore experiences of ‘review and revise’ and stopping,
and to elicit feedback on the proposed intervention and its
implementation.
This provided a better understanding of HCPs’ previous experi-
ences of initiatives around prescribing, the current context of anti-
biotic prescribing in hospitals, and potential barriers and facilitators
to ‘review and revise’ and the implementation of ARK. In-depth
think-aloud interviews added more detailed information about
reactions to the online tool from a broader sample of HCPs. These
methods underpinned the planning, development and optimiza-
tion of ARK and its implementation to increase its acceptability,
feasibility, and, ultimately, its effectiveness. Crucially, ARK provides
potential suggestions for addressing barriers. This is likely to be
helpful for other initiatives incorporating similar activities.
Research suggests that clinicians can be reluctant to revise
others’ prescriptions due to a culture of ‘non-interference’,12 with
senior clinicians having a strong influence on this process.12,30,31
The current research extends this, highlighting the role of poor
communication about the reason for and degree of uncertainty
about the need to initially prescribe antibiotics. This was reportedly
a key barrier, and resulted in the development of one of the core
elements of the intervention: the ARK Decision Aid. Prior research
Preparation
Start thinking about
the implementation
and identify the ARK
core team
Phase 1
Phase 2
Phase 3
Phase 4
Phase 5
Phase 6
Phase 7
ARK core team meet
and plan the start of
the implementation
ARK core team
identify the wider
team and organise the
kick-off meetings
Kick off meetings
Start of the
implementation
Monitoring and
regular discussion of
the implementation
Ensure long-term
sustainability and
championship of
ARK
From
joining ARK
programme
–3 months
–2 months
–2 weeks
Week 1
Ongoing
Post-
implementation
Planning and
piloting
Organise
kick-off
Get ready for
implementation
Implementation
starts
Ongoing
implementation
Long-term
sustainability
Figure 3. ARK phases of implementation.
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has identified that stopping antibiotics ‘early’ is perceived as risky,
and that junior doctors in particular may lack confidence in this.31
Some clinicians report scepticism regarding guidelines for stopping
antibiotics.32 This was also found here, further highlighting that
beliefs about the need to ‘continue the (antibiotic) course’ are a
barrier to ‘review and revise’.33 This informed the development of
another core element of the intervention: the online tool, which
provided a rationale for ‘review and revise’ and evidence for shorter
versus longer courses of antibiotics.
Stakeholder consultation highlighted that the intervention
needed to consider the wide range of hospital contexts that ARK
could be implemented in and the different HCP groups that it could
affect. This led to the development of multi-faceted tools to
support flexible implementation depending on local needs, which
targeted all members of the clinical team (doctors, nurses and
pharmacists). Previous studies have identified a lack of clear/
agreed roles for pharmacists/nurses in ‘review and revise’, and a
perception that ‘review and revise’ was the responsibility of pre-
scribers.34,35 Although these findings emerged in Australia, where
pharmacists and nurses cannot prescribe, and may apply less
to the UK, a key benefit of ARK is its inclusive nature, with both
prescribers and non-prescribers supporting ‘review and revise’ as a
team.
Research into barriers and facilitators to implementing
antimicrobial stewardship initiatives has focused on existing pro-
grammes that have usually been running for >1 year,36–38 so little
is known about barriers to implementing new initiatives. However,
both organizational culture and availability of resources have been
identified as important for implementation.36,38 There has been lit-
tle research into the acceptability and feasibility of particular inter-
vention components and how best to implement them.37
Particular implementation barriers for ARK included: lack of uptake
of the online tool due to negative perceptions of e-learning; poor
attendance at seminars, suggesting the need to integrate with
existing meetings; and uncertainty about how to integrate the
Decision Aid categories into practice. All of these barriers informed
the development of the intervention and its implementation.
For example, the online tool was designed to be brief (7–10 min)
and engaging, and a range of suggestions for different ways to
implement ARK were provided.
A major strength of this research was the use of stakeholder
consultation throughout planning, development and optimization
of ARK and its implementation, which previously has been lacking
in the field.19 This agile new method allowed the research team to
rapidly understand and respond to target users’ needs and
views.20 This permitted dialogue between researchers and key
stakeholders and facilitated the co-creation of intervention mate-
rials. It was an efficient method for developing and testing initial
ideas for the intervention and its implementation. It was neverthe-
less vital to complement stakeholder consultation with in-depth
qualitative research with a more representative and diverse
sample from the target user population. Stakeholder workshop
attendees were enthusiastic, exceptionally well-informed volun-
teers, most of whom had an interest in antimicrobial stewardship.
A large proportion were clinicians. Pharmacists were under-
represented at earlier stages of development, and nurses through-
out. They therefore did not fully represent the target population.
Moreover, stakeholder workshops cannot provide the detailed, in-
dividual feedback that was obtained by using qualitative research
methods. The think-aloud interviews collected structured, in-
depth data on participants’ personal reactions to every element of
intervention content, and were undertaken with a range of staff
groups and grades who were involved in antibiotic prescription and
administration but not necessarily antimicrobial stewardship.
These interviews revealed crucially different views that the inter-
vention needed to address.
One programme is unlikely to fit all needs; however, a good so-
lution might be to provide a toolkit and advice based on potential
barriers to allow implementation based on local needs.37 ARK
fits well with this approach, being explicitly designed to address
barriers and facilitators to stopping antibiotics at ‘review and re-
vise’ and implementation. A key issue in translating interventions
into practice is finding the balance between intervention fidelity
and the need for adaptation.39 Adaptation is integral to ARK,
designed to support its translation into practice. This need was
highlighted by stakeholders as a key design feature to support im-
plementation across diverse hospital contexts. Identifying imple-
mentation barriers and facilitators and defining and developing
antimicrobial stewardship initiatives have both been identified as
research priorities.40 Nonetheless, further research is needed to as-
sess how well this works in practice. ARK’s acceptability, feasibility
and effectiveness also needs to be established. A feasibility trial in
one hospital has already been undertaken; initial results suggest
that ARK is acceptable and feasible to both HCPs and patients. ARK
is now being tested in a stepped-wedge randomized controlled
trial at acute NHS hospitals, which will include a full process evalu-
ation. The ARK online tool has now been made freely available at
http://bsac-vle.com/ark-the-antibiotic-review-kit/, and the imple-
mentation resources are freely available at http://antibioticreview
kit.org.uk/.
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